0000000000959759

AUTHOR

S. Moreno

showing 12 related works from this author

Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

2021

BACKGROUND: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 10 9 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. OBJECTIVE: To estimate the long-term risk difference for cancer with the immediate ART strategy.DESIGN: Multinational prospective cohort study.SETTING: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included…

MaleHIV AIDSHIV Infections0302 clinical medicineInterquartile rangeRisk FactorsNeoplasmsMedicine030212 general & internal medicineProspective StudiesProspective cohort study0303 health sciencesIncidenceAbsolute risk reductionDrugsGeneral MedicineMiddle AgedViral LoadAntiretroviral therapy3. Good healthAIDSCancer treatmentPrevention policy and public healthCohortInfectious diseasesCohort studiesFemaleViral loadAdultmedicine.medical_specialtyAnti-HIV AgentsHIV Infections/drug therapySocio-culturaleTime-to-Treatment03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingInternal medicineInternal MedicineHumansAdverse effect030306 microbiologybusiness.industryHIVCancermedicine.diseaseCD4 Lymphocyte CountCancer.Anti-HIV Agents/therapeutic use[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessNeoplasms/epidemiologyAnnals of Internal Medicine
researchProduct

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

2016

Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.

MaleHuman immunodeficiency virus 1EtravirineRNA directed DNA polymerase inhibitordarunavirHIV InfectionsSettore MED/42 - Igiene Generale E Applicata:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Salud públicageneticsInhibidores de proteasas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]atazanavirmedia_commontransmission:Geographicals::Geographic Locations::Europe [Medical Subject Headings]3. Good healthmicrobial sensitivity testpriority journalEurope ; HIV-1 ; antiretroviral therapy ; drug resistance ; transmissionHIV/AIDSlamivudineReverse Transcriptase Inhibitors/pharmacologyanti human immunodeficiency virus agentDrugMicrobiology (medical)medicine.medical_specialtyantiviral susceptibility:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]media_common.quotation_subjectantiretroviral therapy030106 microbiologyHIV Infections/drug therapy:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors [Medical Subject Headings]Microbial Sensitivity TestsRILPIVIRINEArticleEFAVIRENZ03 medical and health sciencestransmitted drug resistanceSDG 3 - Good Health and Well-beingHumansTransmissionhuman:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance [Medical Subject Headings]REVERSE-TRANSCRIPTASE INHIBITORSRilpivirinaINTEGRASEMUTATIONSabacavirmajor clinical studyVirologyInfecciones por VIHRegimenAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Medicine (all); Microbiology (medical); Infectious DiseaseschemistryDrug resistance:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings]MutationHIV-10301 basic medicinenevirapineDrug resistanceCommunicable diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings]chemistry.chemical_compoundantiviral therapyINFECTIONMedicine and Health SciencesPrevalence:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]ViralNon-U.S. Gov'tReverse-transcriptase inhibitorantiretrovirus agentResearch Support Non-U.S. Gov'tMedicine (all)Human immunodeficiency virus infected patientMiddle AgedvirologyPREVALENCEAntiretroviral therapyEncuestas y CuestionariosANTIRETROVIRAL TREATMENTEuropeInfectious DiseasesHIV-1/drug effectsHIV Protease Inhibitors/pharmacologyRilpivirineReverse Transcriptase Inhibitors:Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings]FemaleHIV drug resistancemedicine.drugAdultHuman immunodeficiency virus proteinase inhibitor:Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings]EfavirenzAnti-HIV AgentsResearch SupportResistencia a medicamentosSettore MED/17 - MALATTIE INFETTIVEantiviral resistanceInternal medicineAnti-HIV Agents/pharmacologyDrug Resistance ViralJournal Articlemedicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors [Medical Subject Headings]abacavir plus lamivudineEuropa (Continente)Antiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Adult; Anti-HIV Agents; Drug Resistance Viral; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Microbiology (medical); Infectious DiseasesemtricitabinenonhumanIntervalos de confianzadrug resistanceMutaciónAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmissionbusiness.industryHIVpredictionInhibidores de la transcriptasa inversaHIV Protease InhibitorsHuman immunodeficiency virus 1 infectiontenofovirINDIVIDUALSDrug Resistance Viral/geneticsBenzoxazinasETRAVIRINEdrug effects3121 General medicine internal medicine and other clinical medicinePrevalenciabusiness
researchProduct

Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

2020

Abstract Background High uptake of antiretroviral treatment (ART) is essential to reduce human immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care exist. We aimed to construct the continuum of HIV care (CoC) in 2016 in 11 European Union (EU) countries, overall and by key population and sex. To estimate progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013 estimates for the same countries, representing 73% of the population in the region. Methods A CoC with the following 4 stages was constructed: number of people living with HIV (PLHIV); proportion of PLHIV diagnosed; proportion of those diagnosed …

Male0301 basic medicinePsychological interventionHuman immunodeficiency virus (HIV)MedizinContinuum of care; Europe; HIV infection; Key population; Sex; Anti-Retroviral Agents; Continuity of Patient Care; European Union; HIV; Humans; Male; HIV InfectionsHIV InfectionsContinuum of care; Europe; HIV infection; Key population; Sexmedicine.disease_causekey population0302 clinical medicineContinuum of careHIV Infection030212 general & internal medicineMen having sex with menContinuum of caremedia_commoneducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTransmission (medicine)Continuity of Patient CareEuropeInfectious DiseasesAcademicSubjects/MED00290Anti-Retroviral AgentsHIV infection continuum of care sex key population EuropeSexMicrobiology (medical)PopulationSocio-culturale03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unioneducationPandemicsHIV infection ; continuum of care ; sex ; key population ; Europebusiness.industrySARS-CoV-2COVID-19HIVmedicine.diseaseHIV infectioncontinuum of care030112 virologyMajor Articles and CommentariesKey populationAnti-Retroviral Agentbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDemography
researchProduct

Search for $B^0_s-\overline{B^0_s}$ oscillations and a measurement of $B^0_d-\overline{B^0_d}$ oscillations using events with an inclusively reconstr…

2003

Neutral B meson oscillations in the B-s(0) - , and B-d(0) - systems were studied using a sample of about 4.0 million hadronic Z decays recorded by the DELPHI detector between 1992 and 2000. Events with a high transverse momentum lepton were removed and a sample of 770 k events with an inclusively reconstructed vertex was selected. The mass difference between the two physical states in the B-d(0) - system was measured to be: Deltam(d) = (0.531 +/- 0.025(stat.) +/- 0.007(syst.))ps(-1). The following limit on the width difference of these states was also obtained: DeltaGamma(Bd)/Gamma(Bd) oscillations was found, a limit on the mass difference of the two physical states was given:, Deltam(s) > …

PhysicsParticle physicsPhysics and Astronomy (miscellaneous)010308 nuclear & particles physicsPhysicsElectron–positron annihilationHadron01 natural sciencesVertex (geometry)Nuclear physics0103 physical sciencesTransverse momentumHigh Energy Physics::ExperimentB meson010306 general physicsEngineering (miscellaneous)LeptonThe European Physical Journal C
researchProduct

Sistema inteligente para protocolizar el diagnóstico de invasión ganglionar en el cáncer de laringe

2002

Laryngeal carcinoma is the most frequent malignant tumour in head and neck. Node invasion is known to be one of the most important prognostic factors. The aim of this study has been to design an intelligent system to perform a diagnostic algorithm of metastasic neck nodes. 122 clinical reports of patients diagnosed of laryngeal carcinoma in our department have been reviewed. The compiled data have been: tumor site, T stage, N stage (clinical, after CT scan and post-surgery). The method used to design the intelligent system has been the ID3, which is able to generate a minimal decision tree. Palpation has been the variable that has given more information about node invasion. CT has proved to…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryDiagnostic testComputed tomographyDiagnostic algorithmsmedicine.diseasePalpationTumor siteSurgeryOtorhinolaryngologymedicineCarcinomaT-stageRadiologyHead and neckbusinessActa Otorrinolaringológica Española
researchProduct

Controlling Domains with High Levels of Hysteresis Using Qualitative Modelling

1997

Abstract Dans ce papier, on se propose I'architecture d'un systeme expert pour controle a temps reel basee sur un modele qualitatif- Le susteme de controle utilise le modele qualitatif pour predire problemes futures et pour manier dounees incompletes et imprecises des sensors. Cettes habilites sout tres precieses pour controler systemes avec une grande niveau d'hysteresis, et foumissent un controle doux et rapide. Nous avans applique l'architecture proposee a le domaine du control de trafic urbain, caracterise par grandes problemes d'hysteresis.

Real-time Control SystemComputer scienceSystems designcomputer.software_genreHumanitiescomputerExpert systemIFAC Proceedings Volumes
researchProduct

A measurement of the branching fractions of the b quark into charged and neutral b hadrons

2003

The production fractions of charged and neutral b-hadrons in b-quark events from Z0 decays have been measured with the DELPHI detector at LEP. An algorithm has been developed, based on a neural network, to estimate the charge of the weakly-decaying b-hadron by distinguishing its decay products from particles produced at the primary vertex. From the data taken in the years 1994 and 1995, the fraction of bbar-quarks fragmenting into positively charged weakly-decaying b-hadrons has been measured to be: f^+ = (42.09 +/- 0.82 (stat.) +/- 0.89 (syst.))%. Subtracting the rates for charged Xibar_b^+ and Omegabar_b^+ baryons gives the production fraction of B^+ mesons: f_Bu = (40.99 +/- 0.82 (stat.)…

QuarkParticle physicsNuclear and High Energy PhysicsMesonElectron–positron annihilationHadronNuclear TheoryFOS: Physical sciencesLIFETIMEBranching (polymer chemistry)01 natural sciencesBottom quarkOmegaHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsNuclear ExperimentZ-DECAYSDELPHIPhysicsBARYONS010308 nuclear & particles physicsPhysicsHigh Energy Physics::PhenomenologyLEPMESONSLARGE ELECTRON POSITRON COLLIDERBaryonPARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; DELPHIZ-DECAYS; LIFETIME; BARYONS; MESONS; LEPPARTICLE PHYSICSHigh Energy Physics::ExperimentParticle Physics - Experiment
researchProduct

Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP)

2018

Purpose: To evaluate differences in the characteristics and outcomes of intensive care unit (ICU) patients over time. Methods: We reviewed all epidemiological data, including comorbidities, types and severity of organ failure, interventions, lengths of stay and outcome, for patients from the Sepsis Occurrence in Acutely ill Patients (SOAP) study, an observational study conducted in European intensive care units in 2002, and the Intensive Care Over Nations (ICON) audit, a survey of intensive care unit patients conducted in 2012. Results: We compared the 3147 patients from the SOAP study with the 4852 patients from the ICON audit admitted to intensive care units in the same countries as those…

MaleOriginalEpidemiology[SDV]Life Sciences [q-bio]HSJ UCIlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]MULTICENTERclinical outcomemortality rateCritical Care and Intensive Care Medicineintensive care unitlaw.invention0302 clinical medicineSeverity of diseaselawEpidemiologymiddle agedMedicine and Health SciencesFAILURE030212 general & internal medicineHospital Mortalityintensive care units -- analysis -- epidemiology -- mortalityGeneralLiterature_REFERENCE(e.g.dictionariesencyclopediasglossaries)CODEScomparative studyintensive careMedicine(all)multilevel analysiIncidenceadultSciences bio-médicales et agricolesIntensive care unit3. Good healthEuropesepsaIntensive Care UnitsfemaleCohortenote intenzivne terapije -- analiza -- epidemiologija -- umrljivostHumanAdultmedicine.medical_specialtyseverity of diseaseCritical CareSepsiIntensive Care UnitUNITED-STATES610 Medicine & healthINTENSIVE-CAREEuropeanArticleSepsisEpidemiology; Sepsis; Severity of disease03 medical and health sciencesAll institutes and research themes of the Radboud University Medical Centerlength of staymaleEpidemiology; Sepsis; Severity of disease; Adult; Europe; Hospital Mortality; Humans; Length of Stay; Male; Critical Care; Intensive Care Units; SepsisAnesthesiologyIntensive careSepsisSCOREmedicineudc:614.2Humanshumanoutcome assessmentSeptic shockbusiness.industrySEPTIC SHOCK030208 emergency & critical care medicineLength of Staymedicine.diseaseTRENDSmajor clinical studySEVERE SEPSIScomorbidity assessmentEmergency medicineEpidemiology; Sepsis; Severity of disease; Critical Care and Intensive Care MedicineObservational studyCLAIMSbusinessSepsis;Severity of disease;Epidemiologyresnost bolezni
researchProduct

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive …

2012

Background: The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission. While compensatory mutations increase fitness during treatment, their presence may also modulate viral fitness and virulence in absence of therapy and major resistance mutations. We previously designed a modeling technique that quantifies genotypic footprints of in vivo treatment selective pressure, including both drug …

AdultMalelcsh:Immunologic diseases. AllergyAnti-HIV AgentseducationVirulenceHIV InfectionsDrug resistanceBiologySettore MED/42 - Igiene Generale E ApplicataViruspolymorphism03 medical and health sciencesViral ProteinsSDG 3 - Good Health and Well-beingVirologyGenotypeDrug Resistance Viraldrug-naivemedicineHumansProspective Studies030304 developmental biology0303 health sciencesPolymorphism Genetic030306 microbiologyResearchproteaseViral LoadVirologyReverse transcriptase3. Good healthCD4 Lymphocyte CountDrug-naïveInfectious Diseases3121 General medicine internal medicine and other clinical medicineImmunologybiology.proteinHIV-1FemaleAntibodylcsh:RC581-607Viral loadHIV-1 infected patientmedicine.drugPeptide HydrolasesRetrovirology
researchProduct

Assessment of the worldwide burden of critical illness: The Intensive Care Over Nations (ICON) audit

2014

Item does not contain fulltext BACKGROUND: Global epidemiological data regarding outcomes for patients in intensive care units (ICUs) are scarce, but are important in understanding the worldwide burden of critical illness. We, therefore, did an international audit of ICU patients worldwide and assessed variations between hospitals and countries in terms of ICU mortality. METHODS: 730 participating centres in 84 countries prospectively collected data on all adult (>16 years) patients admitted to their ICU between May 8 and May 18, 2012, except those admitted for fewer than 24 h for routine postoperative monitoring. Participation was voluntary. Data were collected daily for a maximum of 28 da…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCritical Illnesshealth care facilities manpower and servicesPopulationlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]Critical care european intensive care icon studyComorbidityintensive care medicineGlobal HealthMOF; sepsis; critically ill[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractICON Intensive CareArticleSepsisCohort StudiesOutcome Assessment (Health Care)Intensive careSepsisOutcome Assessment Health CareEpidemiologyHealth careSettore MED/41 - ANESTESIOLOGIAmedicineGlobal healthcritical illness mortalityHumansHospital MortalityeducationIntensive care medicineeducation.field_of_studyMedical Auditbusiness.industryIntensive Caremedicine.diseaseComorbidity3. Good healthIntensive Care UnitsICONbusinessCohort study
researchProduct

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.201…

2016

non presente

Molecular Biology; Cell BiologyCell BiologySettore BIO/06 - Anatomia Comparata E CitologiaMolecular Biology
researchProduct

Search for neutral MSSM Higgs bosons at LEP

2006

The four LEP collaborations, ALEPH, DELPHI, L3 and OPAL, have searched for the neutral Higgs bosons which are predicted by the Minimal Supersymmetric Standard Model (MSSM). The data of the four collaborations are statistically combined and examined for their consistency with the background hypothesis and with a possible Higgs boson signal. The combined LEP data show no significant excess of events which would indicate the production of Higgs bosons. The search results are used to set upper bounds on the cross-sections of various Higgs-like event topologies. The results are interpreted within the MSSM in a number of "benchmark" models, including CP-conserving and CP-violating scenarios. Thes…

AlephPARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; ALEPH; DELPHI; L3; OPALPhysics and Astronomy (miscellaneous)Parameter space01 natural sciencesOPAL DETECTORHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Event (probability theory)BosonPhysicsEXPLICIT CP VIOLATIONROOT-S=189 GEVOPALFLAVOR INDEPENDENT SEARCHParticle physics - ExperimentPhysicsSettore FIS/01 - Fisica SperimentaleHiggs particle. search forSUPERGAUGE TRANSFORMATIONSALEPHLARGE ELECTRON POSITRON COLLIDERALEPH DELPHI L3 OPALSUPERSYMMETRIC STANDARD MODELROOT-SL3Higgs bosonPARTICLE PHYSICSParticle physicselectron positron. colliding beamselectron positron. annihilationFOS: Physical sciencessupersymmetric standard model;; explicit cp violation;; electric-dipole moment;; e(+)e(-) collisions;; root-s=189 gev;; opal detector;; root-s;; z(0) decays;; supergauge transformations;; radiative-correctionsHiggs particle. electroproductionddc:500.2-SUPERSYMMETRIC STANDARD MODEL; EXPLICIT CP VIOLATION; FLAVOR INDEPENDENT SEARCH; ELECTRIC-DIPOLE MOMENT; E(+)E(-) COLLISIONS; ROOT-S; ROOT-S=189 GEV; OPAL DETECTOR; Z(0) DECAYS; SUPERGAUGE TRANSFORMATIONSHiggs particleLEP colliderNext-to-Minimal Supersymmetric Standard ModelELECTRIC-DIPOLE MOMENTE(+)E(-) COLLISIONSConsistency (statistics)0103 physical sciencesddc:530High Energy Physics010306 general physicsEngineering (miscellaneous)DELPHIelectron positron010308 nuclear & particles physicsHigh Energy Physics::PhenomenologyHiggs BosonLEPHIGGSHiggs boson standard modelZ(0) DECAYSExperimental High Energy PhysicsHigh Energy Physics::ExperimentHiggs Boson; LEP colliderMSSMMinimal Supersymmetric Standard ModelHiggs
researchProduct